Latest Insider Transactions at Becton Dickinson & CO (BDX)
This section provides a real-time view of insider transactions for Becton Dickinson & CO (BDX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of BECTON DICKINSON & CO to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of BECTON DICKINSON & CO's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 25
2022
|
Catherine M Burzik Director |
BUY
Grant, award, or other acquisition
|
Direct |
820
+6.16%
|
-
|
|
Jan 25
2022
|
Marshall O Larsen Director |
BUY
Grant, award, or other acquisition
|
Direct |
820
+3.33%
|
-
|
|
Jan 25
2022
|
David F Melcher Director |
BUY
Grant, award, or other acquisition
|
Direct |
820
+11.71%
|
-
|
|
Jan 25
2022
|
Timothy M Ring Director |
BUY
Grant, award, or other acquisition
|
Direct |
820
+1.04%
|
-
|
|
Jan 25
2022
|
Carrie L Byington Director |
BUY
Grant, award, or other acquisition
|
Direct |
820
+44.04%
|
-
|
|
Jan 25
2022
|
R Andrew Eckert Director |
BUY
Grant, award, or other acquisition
|
Direct |
820
+11.65%
|
-
|
|
Jan 25
2022
|
Jeffrey William Henderson Director |
BUY
Grant, award, or other acquisition
|
Direct |
820
+17.84%
|
-
|
|
Jan 25
2022
|
Claire Pomeroy Director |
BUY
Grant, award, or other acquisition
|
Direct |
820
+7.59%
|
-
|
|
Jan 25
2022
|
Bertram L Scott Director |
BUY
Grant, award, or other acquisition
|
Direct |
820
+2.51%
|
-
|
|
Jan 25
2022
|
Christopher Ian Montague Jones Director |
BUY
Grant, award, or other acquisition
|
Direct |
820
+4.2%
|
-
|
|
Dec 16
2021
|
Betty D Larson EVP HR & CHRO |
SELL
Open market or private sale
|
Direct |
3,341
-19.1%
|
$851,955
$255.0 P/Share
|
|
Dec 16
2021
|
Betty D Larson EVP HR & CHRO |
SELL
Sale (or disposition) back to the issuer
|
Direct |
341
-3.57%
|
$86,955
$255.0 P/Share
|
|
Dec 16
2021
|
Betty D Larson EVP HR & CHRO |
BUY
Exercise of conversion of derivative security
|
Direct |
893
+8.55%
|
$86,621
$97.14 P/Share
|
|
Dec 07
2021
|
Thomas J Spoerel SVPController & Chief Acct Off |
SELL
Open market or private sale
|
Direct |
233
-17.76%
|
$58,250
$250.0 P/Share
|
|
Nov 26
2021
|
James C Lim Executive Vice President |
BUY
Grant, award, or other acquisition
|
Direct |
893
+4.14%
|
-
|
|
Nov 26
2021
|
Christopher Del Orefice EVP & Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,608
+27.24%
|
-
|
|
Nov 26
2021
|
Antoine C Ezell EVP, President Americas & CMO |
BUY
Grant, award, or other acquisition
|
Direct |
758
+8.45%
|
-
|
|
Nov 26
2021
|
David Hickey EVP & President, Life Sciences |
BUY
Grant, award, or other acquisition
|
Direct |
1,473
+22.55%
|
-
|
|
Nov 26
2021
|
Thomas J Spoerel SVPController & Chief Acct Off |
BUY
Grant, award, or other acquisition
|
Direct |
489
+16.08%
|
-
|
|
Nov 26
2021
|
Thomas J Spoerel SVPController & Chief Acct Off |
SELL
Payment of exercise price or tax liability
|
Direct |
195
-15.98%
|
-
|
|
Nov 26
2021
|
Christopher R Reidy CFO and EVP of Administration |
BUY
Grant, award, or other acquisition
|
Direct |
4,998
+7.5%
|
-
|
|
Nov 26
2021
|
Christopher R Reidy CFO and EVP of Administration |
SELL
Payment of exercise price or tax liability
|
Direct |
1,132
-3.81%
|
-
|
|
Nov 26
2021
|
Betty D Larson EVP HR & CHRO |
BUY
Grant, award, or other acquisition
|
Direct |
2,656
+13.75%
|
-
|
|
Nov 26
2021
|
Betty D Larson EVP HR & CHRO |
SELL
Payment of exercise price or tax liability
|
Direct |
580
-7.81%
|
-
|
|
Nov 26
2021
|
Ribo Alberto Mas EVP and Pres, Life Sciences |
BUY
Grant, award, or other acquisition
|
Direct |
3,802
+14.69%
|
-
|
|
Nov 26
2021
|
Ribo Alberto Mas EVP and Pres, Life Sciences |
SELL
Payment of exercise price or tax liability
|
Direct |
798
-7.71%
|
-
|
|
Nov 26
2021
|
Samrat S. Khichi EVP and General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
2,904
+19.81%
|
-
|
|
Nov 26
2021
|
Samrat S. Khichi EVP and General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
681
-13.43%
|
-
|
|
Nov 26
2021
|
Alexandre Conroy EVP of Integrated Supply Chain |
BUY
Grant, award, or other acquisition
|
Direct |
2,535
+5.68%
|
-
|
|
Nov 26
2021
|
Alexandre Conroy EVP of Integrated Supply Chain |
SELL
Payment of exercise price or tax liability
|
Direct |
863
-4.15%
|
-
|
|
Nov 26
2021
|
Roland Goette EVP and President, EMEA |
BUY
Grant, award, or other acquisition
|
Direct |
937
+4.43%
|
-
|
|
Nov 26
2021
|
Roland Goette EVP and President, EMEA |
SELL
Payment of exercise price or tax liability
|
Direct |
31
-0.32%
|
-
|
|
Nov 26
2021
|
Simon D Campion EVP and Segment President |
BUY
Grant, award, or other acquisition
|
Direct |
2,775
+12.0%
|
-
|
|
Nov 26
2021
|
Simon D Campion EVP and Segment President |
SELL
Payment of exercise price or tax liability
|
Direct |
650
-6.87%
|
-
|
|
Nov 26
2021
|
Thomas E Polen Jr Chairman, CEO and President |
BUY
Grant, award, or other acquisition
|
Direct |
13,369
+19.47%
|
-
|
|
Nov 26
2021
|
Thomas E Polen Jr Chairman, CEO and President |
SELL
Payment of exercise price or tax liability
|
Direct |
1,913
-9.47%
|
-
|
|
Nov 16
2021
|
Roland Goette EVP and President, EMEA |
SELL
Payment of exercise price or tax liability
|
Direct |
1,914
-16.96%
|
$467,016
$244.11 P/Share
|
|
Nov 16
2021
|
Roland Goette EVP and President, EMEA |
BUY
Exercise of conversion of derivative security
|
Direct |
3,055
+21.3%
|
$219,960
$72.12 P/Share
|
|
Oct 21
2021
|
Carrie L Byington Director |
BUY
Grant, award, or other acquisition
|
Direct |
221
+50.0%
|
-
|
|
Sep 08
2021
|
Rebecca W Rimel Director |
SELL
Open market or private sale
|
Direct |
500
-4.5%
|
$130,000
$260.0 P/Share
|
|
Sep 08
2021
|
David Hickey EVP & President, Life Sciences |
SELL
Open market or private sale
|
Direct |
500
-12.24%
|
$130,000
$260.0 P/Share
|
|
Sep 08
2021
|
Thomas J Spoerel SVPController & Chief Acct Off |
SELL
Open market or private sale
|
Direct |
267
-20.78%
|
$69,420
$260.0 P/Share
|
|
Sep 07
2021
|
Christopher Del Orefice EVP & Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
4,359
+50.0%
|
-
|
|
Sep 04
2021
|
David Hickey EVP & President, Life Sciences |
SELL
Payment of exercise price or tax liability
|
Direct |
268
-6.16%
|
-
|
|
Sep 03
2021
|
James C Lim Executive Vice President |
SELL
Open market or private sale
|
Direct |
6,956
-26.03%
|
$1,787,692
$257.44 P/Share
|
|
Sep 03
2021
|
James C Lim Executive Vice President |
SELL
Sale (or disposition) back to the issuer
|
Direct |
7,628
-22.21%
|
$1,960,396
$257.44 P/Share
|
|
Sep 03
2021
|
James C Lim Executive Vice President |
BUY
Exercise of conversion of derivative security
|
Direct |
14,584
+29.8%
|
$1,954,256
$134.73 P/Share
|
|
Sep 03
2021
|
Rebecca W Rimel Director |
SELL
Open market or private sale
|
Direct |
500
-4.3%
|
$128,500
$257.1 P/Share
|
|
Sep 02
2021
|
Rebecca W Rimel Director |
SELL
Open market or private sale
|
Direct |
244
-2.06%
|
$61,976
$254.0 P/Share
|
|
Aug 30
2021
|
Rebecca W Rimel Director |
SELL
Open market or private sale
|
Direct |
207
-1.72%
|
$52,164
$252.0 P/Share
|